Statins may Decrease Aneurysm wall Enhancement of Unruptured Fusiform Intracranial Aneurysms: A high-resolution 3T...

No prior work had resolved whether systemic anti-inflammatory therapies influence the localized inflammatory state of unruptured fusiform intracranial aneurysms. Prior research has shown that wall inflammation drives the development and eventual rupture of these vascular abnormalities. High-resolution magnetic resonance imaging provides a non-invasive window into these pathological changes through the observation of wall enhancement. That uncertainty drove the need to evaluate if common medications could modulate this specific imaging biomarker. Previous clinical observations have linked statin therapy to reduced vascular inflammation in other arterial territories. However, the specific impact of these drugs on intracranial fusiform lesions remained largely uncharacterized. This gap motivated a systematic investigation into the relationship between pharmacological interventions and vessel wall signals. The current study addresses this by quantifying the association between statin exposure and imaging-based markers of instability.

The primary aim of this investigation was to determine the correlation between anti-inflammatory drug use and three-dimensional wall enhancement in fusiform intracranial aneurysms. Researchers sought to clarify if common medications could modulate the inflammatory state of these unruptured vascular lesions. The study addressed the hypothesis that systemic pharmaceutical interventions might influence localized imaging biomarkers of aneurysm instability. By focusing on fusiform morphologies, the team intended to explore potential differences in pathophysiology among various aneurysm types. This work was motivated by the need to identify non-invasive indicators of vascular health and potential therapeutic targets. The authors aimed to provide objective data on how statins might affect the vessel wall environment. They specifically examined whether long-term medication use could lead to measurable changes in signal intensity on high-resolution scans. This research effort ultimately strives to improve the clinical assessment of aneurysm rupture risk through pharmacological analysis.

The investigators conducted a retrospective review of clinical databases to identify patients with fusiform intracranial aneurysms. Their review approach involved screening for individuals who underwent high-resolution 3T magnetic resonance imaging at three distinct Chinese medical centers. The team categorized all identified lesions into three specific morphological groups: fusiform, dolichoectatic, and transitional types. To quantify the imaging biomarker, they calculated the ratio of signal intensity between the aneurysm wall and the pituitary stalk. This calculation utilized post-contrast T1-weighted sequences to ensure standardized measurements across the entire cohort. The researchers also gathered comprehensive clinical information, including patient demographics, co-existing medical conditions, and specific aneurysm characteristics. Statistical evaluation employed univariate and multivariate logistic regression models to identify independent predictors of the observed imaging signals. Finally, they performed correlation analyses to assess the relationship between medication history and the specific morphological subtypes identified in the study.

The strongest finding indicates that statin use serves as the only independent factor significantly associated with decreased wall enhancement. Multivariate analysis confirmed this relationship with a beta coefficient of -0.236 and a p-value of 0.007. The study included a total of 127 fusiform intracranial aneurysms across all examined categories. Regarding subtype analysis, fusiform types showed a significant association with statin use, represented by a correlation coefficient of -0.230. Transitional types exhibited an even stronger association with the medication, yielding a correlation coefficient of -0.551. These results suggest that the protective effect of the drug is not uniform across all vascular morphologies. The researchers established that daily statin intake for at least six months is linked to these lower imaging signals. These findings provide quantitative evidence that systemic therapy may influence the inflammatory state of unruptured intracranial lesions.

The authors propose that long-term statin administration correlates with diminished wall enhancement in fusiform intracranial aneurysms. Their analysis suggests that these medications might exert a stabilizing influence on the vascular wall by mitigating inflammatory processes. The researchers highlight that this effect appears most pronounced in specific morphological subtypes of these aneurysms. These findings imply that the underlying biological mechanisms driving wall inflammation may vary significantly across different aneurysm classifications. The study provides evidence that pharmacological modulation of the vessel wall is detectable via advanced imaging techniques. By establishing this link, the authors suggest a potential therapeutic avenue for managing unruptured vascular lesions. Future clinical management strategies could consider these associations when assessing the risk profile of individual patients. The data emphasize that systemic drug use may have localized benefits for intracranial vascular health.